Day: December 20, 2023

Screening libraries will leverage Recursion’s MatchMaker tool to identify compounds across Enamine REAL Space predicted to bind to high-value targets. KYIV, Ukraine and SALT LAKE CITY, Dec. 20, 2023 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its partnership with Enamine, a world-renowned provider of novel molecules and contract research services, to generate enriched screening libraries with insights from Recursion’s protein-ligand interaction predictions spanning across Enamine’s massive library of 36 billion compounds.Chris Gibson, CEO and Co-founder of Recursion, traveled to Kyiv to sign this partnership deal with Andrey Tolmachov, CEO and Founder of Enamine. “I’m thrilled to announce this partnership as we continue...

The Company signed a non-binding letter of intent to invest $2.5 million for a 70% stake in a new company to be incorporated that will develop laser- based charging solutions for drones and unmanned aircrafts Tel Aviv, Israel, Dec. 20, 2023 (GLOBE NEWSWIRE) — Jeffs’ Brands Ltd (“Jeffs’ Brands” or the “Company”) (Nasdaq: JFBR, JFBRW), a data-driven e-commerce company operating on the Amazon Marketplace, signed an additional non-binding letter of intent (“LOI”) with Sky Growth Partners Ltd. (“Sky Growth”), to invest in advanced laser- based wireless power transmission technology systems, for the remote charging of drones and unmanned aircrafts (the “Investment”). The LOI, previously announced on December 15, 2023, follows the Company’s announcement from November 29, 2023, in which the board of directors resolved to identify...

Reflects continued focus on adding intellectual property to support the strategic direction of the Company to provide a complete solution set for the treatment of carotid artery disease and the prevention of stroke TEL AVIV, Israel and MIAMI, Dec. 20, 2023 (GLOBE NEWSWIRE) — InspireMD (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, announced today the issuance of U.S. Patent No. 11,844,893, titled, “Shunts with Blood Flow Indicators.” The patent covers key aspects of the company’s SwitchGuard™ Neuroprotection System (NPS) along with future features in development that are expected to enable the treating physician to visualize flow through the system. The SwitchGuard™ NPS is designed to allow the physician to reverse blood flow to the brain during...

VANCOUVER, British Columbia, Dec. 20, 2023 (GLOBE NEWSWIRE) — American Pacific Mining Corp (CSE: USGD / OTCQX: USGDF / FWB: 1QC) (“American Pacific” or the “Company”) is pleased to announce that it has received the permits necessary to commence drilling at the Madison Copper-Gold Project (“Madison” or the “Project”) in Montana, USA. The five-hole diamond drill campaign, which is expected to commence in Q1, 2024, is designed to further define and expand on known near-surface, high-grade copper and gold mineralization, while extending beneath known mineralization to provide a foundation for deeper exploration in areas which have seen limited historical drilling. The programs sets out to achieve three key objectives: test shallow gap areas; tighten drill spacing at moderate depth within the skarn to support a future mineral resource...

WATERTOWN, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced that Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint Pharmaceuticals will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 10, 2024 at 10:30 a.m. PT/1:30 p.m. ET. A webcast and subsequent archived replay of the presentation may be accessed via the Investors section of the Company website at www.eyepointpharma.com. About EyePoint Pharmaceuticals EyePoint Pharmaceuticals (Nasdaq: EYPT) is a clinical-stage company committed to developing and commercializing therapeutics to help improve the lives of patients with serious...